St Louis, Missouri 63110

  • Prostate Cancer

Purpose:

This is a prospective, multicenter, open-label, non-randomized study evaluating the ability of [89]Zr-Df-IAb2M to detect local, regional and metastatic prostate cancer confirmed by pathology.


Study summary:

IAB2M is an approximately 80 kDA molecular weight antibody fragment (a "Minibody") chelated with Desferroxamine and radiolabeled with [89]Zr. [89Zr]-Df-IAB2M targets the extracellular domain of Prostate Membrane Specific Antigen (PSMA) expressed on most primary and metastatic prostate cancer lesions. This is a phase 2, prospective, multi-center, open-label, non-randomized study evaluating the ability of [89]Zr-Df-IAb2M to detect local, regional and metastatic prostate cancer confirmed by pathology in patients with biopsy-proven prostate cancer thought to be candidates for radical prostatectomy and pelvic lymph node dissection who are at high-risk for pelvic lymph node metastasis. These patients may have identified lymphadenopathy on conventional imaging but are considered eligible if still judged to be candidates for radical prostatectomy and lymph node dissection.


Criteria:

Inclusion Criteria: 1. Histological diagnosis of prostate adenocarcinoma. 2. Patients considered candidates for radical prostatectomy and pelvic lymph node dissection. These patients may or may not have identified nodal metastasis on conventional imaging but would still be candidates for radical prostatectomy and pelvic lymph node dissection. 3. Patients, who are at high-risk for pelvic lymph node metastasis as defined by a lymph node involvement risk of greater than or equal to 20% using the Briganti nomogram. 4. Age ≥ 18 years. 5. Ability to understand and willingness to sign IRB approved consent form 6. For men of child-producing potential, the use of effective contraceptive methods during the study. Exclusion Criteria: 1. Treatment or plans for treatment with radiation therapy, surgery, chemotherapy, or investigational therapy between the time of conventional imaging, [89]Zr-Df-IAB2M PET/CT and the surgical resection or biopsy procedures used for the study evaluation. 2. Unwillingness or inability to comply with procedures required in this protocol. 3. Other cancers that might potentially interfere with the reading and interpretation of [89]Zr-Df-IAB2M PET/CT scans. 4. Patients who are currently receiving any other investigational agent. 5. Patients who have had or are currently receiving androgen deprivation therapy


NCT ID:

NCT02424513


Primary Contact:

Principal Investigator
James Eastham, MD
Memorial Sloan Kettering Cancer Center

Farrokh Dehdashti, MD
Phone: (314)-362-1474
Email: dehdashtif@mir.wustl.edu


Backup Contact:

N/A


Location Contact:

St Louis, Missouri 63110
United States

Farrokh Dehdashti, MD
Phone: 314-362-1474
Email: dehdashtif@mir.wustl.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.